Akari Therapeutics (AKTX) Assets Average (2012 - 2026)

Akari Therapeutics (AKTX) has reported Assets Average for 13 consecutive years, with $40.9 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average fell 19.44% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (down 19.44% YoY) and the FY2025 annual result came in at $49.2 million, up 79.28% from the prior year.
• Assets Average eased to $40.9 million in Q1 2026 per AKTX's latest filing, from $46.6 million in the prior quarter.
• Over the last five years, Assets Average for AKTX reached as high as $50.9 million in Q2 2025 and fell as low as $3.6 million in Q1 2024.
• A 4-year average of $27.2 million and a median of $26.6 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average jumped 1324.46% — and 2026, when it declined 19.44%.
• Year by year, Assets Average stood at $12.6 million in 2022, then jumped by 111.47% to $26.6 million in 2024, then jumped by 75.0% to $46.6 million in 2025, then slipped by 12.32% to $40.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $40.9 million, $46.6 million, and $48.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.